{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:14:10Z","timestamp":1793459650316,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ebiom.2022.104069","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T14:00:29Z","timestamp":1653055229000},"page":"104069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Safety, tolerability, and anti-fibrotic efficacy of the CBP\/\u03b2-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1\/2a study"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-4721","authenticated-orcid":false,"given":"Kiminori","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanao","family":"Saio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8599-2245","authenticated-orcid":false,"given":"Yoshihiro","family":"Ikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-807X","authenticated-orcid":false,"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Ieiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Todaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terumi","family":"Kamisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10308","key":"10.1016\/j.ebiom.2022.104069_bib0001","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Gines","year":"2021","journal-title":"Lancet"},{"issue":"9615","key":"10.1016\/j.ebiom.2022.104069_bib0002","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104069_bib0003","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Invest"},{"issue":"10319","key":"10.1016\/j.ebiom.2022.104069_bib0004","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ebiom.2022.104069_bib0005","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104069_bib0006","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.09.065","article-title":"Fibrosis regression after eradication of hepatitis C virus: from bench to bedside","volume":"160","author":"Rockey","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104069_bib0007","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.32285","article-title":"Hepatic fibrosis 2022: Unmet needs and a blueprint for the future","volume":"75","author":"Friedman","year":"2022","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104069_bib0008","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including Cilofexor and Firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104069_bib0009","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/hep.30782","article-title":"Report on the AASLD\/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD","volume":"70","author":"Rinella","year":"2019","journal-title":"Hepatology"},{"issue":"10215","key":"10.1016\/j.ebiom.2022.104069_bib0010","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"10213","key":"10.1016\/j.ebiom.2022.104069_bib0011","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104069_bib0012","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","article-title":"Wnt\/beta-Catenin signaling, disease, and emerging therapeutic modalities","volume":"169","author":"Nusse","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104069_bib0013","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/beta-catenin signaling and disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104069_bib0014","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1165\/rcmb.2008-0485TR","article-title":"WNT signaling in lung disease: a failure or a regeneration signal?","volume":"42","author":"Konigshoff","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104069_bib0015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41581-020-00343-w","article-title":"WNT-beta-catenin signalling - a versatile player in kidney injury and repair","volume":"17","author":"Schunk","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104069_bib0016","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.21651","article-title":"WNT\/beta-catenin signaling in liver health and disease","volume":"45","author":"Thompson","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104069_bib0017","doi-asserted-by":"crossref","first-page":"337","DOI":"10.33549\/physiolres.932289","article-title":"Wnt\/beta-catenin signaling: a promising new target for fibrosis diseases","volume":"61","author":"Guo","year":"2012","journal-title":"Physiol Res"},{"issue":"9","key":"10.1016\/j.ebiom.2022.104069_bib0018","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1681\/ASN.2010101079","article-title":"Targeted inhibition of beta-catenin\/CBP signaling ameliorates renal interstitial fibrosis","volume":"22","author":"Hao","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"32","key":"10.1016\/j.ebiom.2022.104069_bib0019","doi-asserted-by":"crossref","first-page":"14309","DOI":"10.1073\/pnas.1001520107","article-title":"Inhibition of Wnt\/beta-catenin\/CREB binding protein (CBP) signaling reverses pulmonary fibrosis","volume":"107","author":"Henderson","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.ebiom.2022.104069_bib0020","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41598-017-00282-w","article-title":"Selective inhibitor of Wnt\/beta-catenin\/CBP signaling ameliorates hepatitis C virus-induced liver fibrosis in mouse model","volume":"7","author":"Tokunaga","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.ebiom.2022.104069_bib0021","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ebiom.2015.10.010","article-title":"Inhibition of cyclic adenosine monophosphate (cAMP)-response element-binding protein (CREB)-binding protein (CBP)\/beta-catenin reduces liver fibrosis in mice","volume":"2","author":"Osawa","year":"2015","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.ebiom.2022.104069_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103103","article-title":"Wnt\/beta-Catenin signaling as a potential target for the treatment of liver cirrhosis using antifibrotic drugs","volume":"19","author":"Nishikawa","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebiom.2022.104069_bib0023","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ebiom.2017.08.016","article-title":"Safety, tolerability, and preliminary efficacy of the anti-fibrotic small molecule PRI-724, a CBP\/beta-catenin inhibitor, in patients with hepatitis C virus-related cirrhosis: a single-center, open-label, dose escalation phase 1 trial","volume":"23","author":"Kimura","year":"2017","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104069_bib0024","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D'Ambrosio","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104069_bib0025","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from HCV-TARGET cohort","volume":"73","author":"Verna","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104069_bib0026","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.20767","article-title":"Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis","volume":"42","author":"Lau","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104069_bib0027","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.510260209","article-title":"Hepatic stellate cell immunodetection and cirrhotic evolution of viral hepatitis in liver allografts","volume":"26","author":"Guido","year":"1997","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104069_bib0028","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.12.003","article-title":"The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104069_bib0029","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hep.29302","article-title":"Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis","volume":"66","author":"Xiao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ebiom.2022.104069_bib0030","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.13758","article-title":"Changes in liver stiffness measurements and fibrosis scores following Sofosbuvir based treatment regimens without Interferon","author":"Elsharkawy","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ebiom.2022.104069_bib0031","article-title":"Baveno VII - Renewing consensus in portal hypertension","author":"de Franchis","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.ebiom.2022.104069_bib0032","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jhep.2018.11.025","article-title":"Non-invasive diagnosis and biomarkers in alcohol-related liver disease","volume":"70","author":"Moreno","year":"2019","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.ebiom.2022.104069_bib0033","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ebiom.2022.104069_bib0034","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of Belapectin, an inhibitor of Galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.ebiom.2022.104069_bib0035","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642200250X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642200250X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:17:13Z","timestamp":1762456633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239642200250X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":35,"alternative-id":["S235239642200250X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104069","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, tolerability, and anti-fibrotic efficacy of the CBP\/\u03b2-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1\/2a study","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104069"}}